

US EPA ARCHIVE DOCUMENT

RECORD NO : 264087
 PC Code No : 122804
 EEB Out :

MAR 26 1992

To: GEORGE LARocca 15
 Product Manager
 Registration Division

From: Douglas J. Urban, Acting Chief
 Ecological Effects Branch/EFED (H7507C)

Attached, please find the EEB review of...

Reg./File # : 618-97
 Chemical Name : Avermectin
 Type Product : Miticide
 Product Name : ZEPHYR 0.15 EC
 Company Name : MERCK SHARP & DOHME
 Purpose : REVIEW ENVIRONMENTAL CHEMISTRY METHOD

Action Code : 305 Date Due : _____
 Reviewer : DAN RIEDER

EEB Guideline/MRID Summary Table: The review in this package contains an evaluation of the following:

GDLN NO	MRID NO	CAT	GDLN NO	MRID NO	CAT	GDLN NO	MRID NO	CAT
71-1(A)			72-2(A)			72-7(A)		
71-1(B)			72-2(B)			72-7(B)		
71-2(A)			72-3(A)			122-1(A)		
71-2(B)			72-3(B)			122-1(B)		
71-3			72-3(C)			122-2		
71-4(A)			72-3(D)			123-1(A)		
71-4(B)			72-3(E)			123-1(B)		
71-5(A)			72-3(F)			123-2		
71-5(B)			72-4(A)			124-1		
72-1(A)			72-4(B)			124-2		
72-1(B)			72-5			141-1		
72-1(C)			72-6			141-2		
72-1(D)						141-5		

Y=Acceptable (Study satisfied Guideline)/Concur
 P=Partial (Study partially fulfilled Guideline but additional information is needed)
 S=Supplemental (Study provided useful information but Guideline was not satisfied)
 N=Unacceptable (Study was rejected)/Nonconcur

1



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

MAR 26 1992

OFFICE OF
PESTICIDES AND TOXIC
SUBSTANCES

MEMORANDUM

SUBJECT: Review of Environmental Chemistry Method for
Avermectin Record # 264087

FROM: Douglas Urban, Acting Chief
Ecological Effects Branch
Environmental Fate and Effects Division H7507C

TO: George LaRocca, PM 15
Insecticide/Rodenticide Branch
Registration Division H7505C

The Ecological Effects Branch has received the Environmental Chemistry Methods (ECM) for Avermectin and has sent them to the Analytical Branch, BEAD for validation. While nothing has come back in writing so far, we have received positive feedback from the chemists concerning the completeness of the methods and supporting information. When the validation process is complete, the EEB will use the conclusions in the review of laboratory and field studies conducted with avermectin. If you have questions, please contact Dan Rieder.

2

